Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil
The Brazilian Health Regulatory Agency has granted an exceptional authorisation for Illuccix® (TLX591-CDx), Telix’s lead prostate cancer imaging product.
Australian TGA Approves Illuccix® for Prostate Cancer Imaging
Australian Therapeutic Goods Administration has approved Illuccix® for the diagnostic imaging of men with prostate cancer.
Activities Report and Appendix 4C for September 2021 Quarter
Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 September 2021.
Telix Establishes Commercial Hub in Geneva, Switzerland
Telix is pleased to announce that it has established a new commercial hub in Geneva through its subsidiary, Telix Pharmaceuticals (Switzerland) GmbH.
Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging
Telix enters a commercial distribution agreement with Radius for Telix’s prostate cancer investigational imaging product Illuccix®
Telix In-Licences Novel Tumour Microenvironment PET Tracer
Telix announces an exclusive licence agreement for a novel PET radiotracer originating from the Université catholique de Louvain.
Telix to Collaborate with Kettering Health on Diagnostic PSMA Imaging & Targeting Theranostics
Telix announces collaboration with Kettering Health on PSMA-targeting theranostics
Michael Didocha Joins Telix as Chief Financial Officer, Americas
Telix is delighted to announce the appointment of Michael Didocha as Chief Financial Officer for the Americas region.
Samantha McSherry Joins Telix as Director of Commercial Operations ANZ
Telix is delighted to announce that Samantha McSherry has joined Telix as Director of Commercial Operations for Australia and New Zealand.
Half Year Shareholder Update
Telix Pharmaceuticals Limited Announces Half-year Shareholder Update